

# DIVERSIFICATION DASHBOARD

September 2015

## Diversification Ratios®

<p>TOBAM's Diversification Ratio® (DR) measures to what extent a portfolio is diversified. The DR<sup>2</sup> (square of the diversification ratio) measures the number of effective degrees of freedom to which a portfolio is exposed.</p> <p>As the table shows, the "broad market" indices leave diversification on the table. In addition to a snapshot of each market's DR<sup>2</sup>, the table shows the DR<sup>2</sup> of a well-diversified portfolio, and the fraction of available diversification used by the index.</p>	Universe	DR <sup>2</sup> Index diversification	DR <sup>2</sup> Maximum diversification®	% diversification used by index
	MSCI All Countries World	4.52	14.54	31.1%
	MSCI World	4.04	12.08	33.5%
	MSCI Emerging Markets	5.47	9.84	55.6%
	MSCI Canada	3.92	7.83	50.1%
	MSCI Pacific Ex-Japan	2.67	6.27	42.5%
	MSCI US Equity	2.65	5.87	45.1%
	MSCI Japan	2.23	4.54	49.2%
	MSCI EMU	1.72	3.65	47.1%
	MSCI UK Equity	2.31	3.62	63.6%
	MSCI Australia	2.15	3.56	60.4%

Source: TOBAM, figures as of August 31, 2015

## Thinking Long-Term

*Our engagement with Amnesty International and Human Rights Watch is core to our investment philosophy and representative of the way we consider our responsibilities as a long-term investor and towards our clients.*

*Since its beginnings, TOBAM has decided that sustainable development would be explicitly core to its values. Our clients have a long-term approach to investing and our sustainable way addresses these concerns.*

*The launch of the Anti-Benchmark Emerging Markets Equity strategy in 2011 led TOBAM to consider its investments in emerging countries and the human rights track record of certain governments.*

*Given that fundamental rights are a principal source of creativity, innovation, fight against corruption and, in a nutshell, economic growth, TOBAM has decided to support Amnesty International and Human Rights Watch whose sole objective is to promote human rights in the world.*

*We have taken the opportunity of the 2015 addition of Human Rights Watch into TOBAM partnership programs to interview Human Rights Watch's senior researcher, [Ole Solvang](#), involved notably in the Mission in Crimea supported by TOBAM.*



### OUR HISTORIC PARTNER: AMNESTY INTERNATIONAL

While investing in Emerging Markets provides capital support to the local economies and communities, it also implicitly supports governments that are not always blameless when it comes to human rights. For this reason, TOBAM supports Amnesty International since the launch of the Anti-Benchmark Emerging Markets Equity strategy in 2011 and donates each year a share of the profits generated from the TOBAM Anti-Benchmark Emerging Markets Equity fund.

Amnesty International is a global movement of more than 7 million people who campaign for a world where human rights are enjoyed by all. Amnesty International's mission is to conduct research and take action to prevent and end grave abuses of all human rights – civil, political, social, cultural and economic. From freedom of expression and association to physical and mental integrity, from protection from discrimination to the right to housing – these rights are indivisible.

Through their detailed research and determined campaigning, they help bring torturers to justice, change oppressive laws and free people jailed just for voicing their opinion.

For example, TOBAM's donation to Amnesty in 2014, helped human rights defenders in the following actions:

- Pressures to release prisoners of conscience and protect human right defenders, such as Meriam Ibrahim, a Christian sentenced to death in Sudan, and finally released in June 2015
- Research and actions on improving the legal framework in countries, as in Morocco, where the parliament recently voted unanimously to amend the law that blocked the prosecution and punishment of any person who, accused of statutory rape, married the victim.
- Campaigning and pressures on officials, which for example led, on December 24, 2014, after two decades of tireless campaigning, the Arms Treaty to come into force (*First international treaty to set out robust global rules to stop the flow of weapons when it is known they would be used to commit human rights violations.*)

Amnesty International is funded mainly by its membership and public donations. No funds are sought or accepted from governments for investigating and campaigning against human rights abuses.



### AN ADDITIONAL ORGANIZATION: HUMAN RIGHTS WATCH

The growing success of the Anti-Benchmark Emerging Markets Equity strategy has led TOBAM this year to include a second partner, Human Rights Watch, in TOBAM's efforts to contribute to human rights developments by financially supporting these two internationally recognized organizations.

Human Rights Watch and Amnesty International share a common mission; to defend human rights worldwide and serve as leading partners in this global movement. Both organizations were originally established in the midst of the cold war, with the objective to defend political prisoners. Both organizations apply the principles set out in the Universal Declaration of Human Rights, the International Humanitarian Law and other international human rights standards as a foundation for their work.

Human Rights Watch is known for the high quality of its research; for its strategic, targeted, high-level advocacy; for the independent reliability of their work, and for the impact they have on the lives of millions of people. The strength of Human Rights Watch is their influential membership, the "grasstops" advocacy—their ability to access world leaders and effect policy change.

TOBAM's initiative with Human Rights Watch helps financing a mission in Ukraine, covering a wide range of issues: use of explosive weapons, landmines, monitoring of the humanitarian situation, illegal detentions and torture, freedom of speech, disappearances in Crimea.

*We decided to support organizations whose sole objective is to promote human rights in the world.*

*Our engagement with Amnesty International and Human Rights Watch is core to our approach and representative of the way we consider our long-term investor's responsibilities.*

*We have taken the opportunity of the 2015 addition of Human Rights Watch into TOBAM partnership programs to interview Human Rights Watch's senior researcher, Ole Solvang, involved notably in the Mission in Crimea supported by TOBAM.*



**Ole Solvang**, Senior researcher in the emergencies division – Human Rights Watch

*Ole works to investigate and expose human rights violations in crisis situations on a rapid-response basis. Since 2001, he has worked for Human Rights Watch in Russia, Kyrgyzstan, Uzbekistan, Georgia, Sri Lanka, Syria and its neighboring countries. He has most recently worked on the crisis in Ukraine, where he has conducted investigations into indiscriminate shelling of civilians. Solvang is featured in the 2014 documentary film "E-Team," which was premiered at the*

*Sundance Film Festival. He has also served as the executive director of Russian Justice Initiative, an organization providing legal aid to victims of human rights violations such as torture, extrajudicial executions, and disappearances in Chechnya and the North Caucasus. Solvang holds a master's degree of international affairs from New York's Columbia University with a focus on international human rights and the former Soviet Union.*

**TOBAM: Could you describe the current situation in Ukraine?**

The crisis in Ukraine has taken many forms since November 2013, when a protest movement denouncing government corruption swept the capital Kiev. Civil unrest and violence quickly spread to other cities and led to the ousting of Ukraine's president in early 2014. Russia's subsequent occupation of Crimea emboldened pro-Russia rebels to seize power in towns and cities across eastern Ukraine—today the epicenter of an international conflict between Russia-backed rebels, Ukraine, and Russia. A ceasefire agreed upon in February has been extremely fragile, and there is still daily fighting and shelling, putting civilians at risk and forcing them to flee their homes. In addition to the fighting, the lack of adequate humanitarian assistance, including life-saving medicines, continues to take a terrible toll on civilians. The conflict has already killed more than 6,000 people and displaced more than a million.

**TOBAM: The fact that you monitor human rights violations and abuses from both sides is one of the reason we decided to support the mission in Crimea, as it felt to us as a strong advocacy for Human Rights - Why do you believe this "no black & white" vision is crucial?**

An armed conflict is never black and white; it never happens that all the good guys are on one side and all the bad guys are on the other side. In the conflicts we cover all over the world, we unfortunately see that all sides commit violations of the laws of war. Of course, some of the warring parties might be better than others. But for a civilian who was tortured, it does not really matter how many other people that side tortured, it is still a violation of his or her rights, and it is our job to document and condemn it. Human Rights Watch maintains strict independence and impartiality in all of the work that we undertake, and documenting abuses by both sides is critical to ensuring that we obtain a full and accurate picture of what is happening on the ground.


**TOBAM: Human Rights Watch accepts no funding from governments to remain 100% free and independent, what are however your relationships with governments? What is the split between monitoring and reporting; and influence change?**

We employ a simple methodology for defending human rights: investigating, exposing, and pushing for change. Our researchers share their findings with governments, international donors, and international

governmental bodies. They press powerful actors to use their influence to curb abuse. Working behind the scenes and drawing upon their on-the-ground experience, our researchers answer questions from political leaders. They have also served as expert witnesses in trials of those responsible for the world's worst crimes.

**TOBAM: What is the day-to-day work of a senior researcher at Human Rights Watch?**

No day is the same. Some days you are in a war zone, investigating, for example, an indiscriminate attack by examining rockets craters, looking for weapons remnants, and interviewing victims and witnesses who have experienced the most horrible things you can imagine. Some days you are locked up in the office, trying to write a press release or report as quickly as possible to draw attention to the human rights violations you have documented. Other days you are doing back-to-back meeting with government officials, some of them hostile, trying to convince them to implement your recommendations so that fewer civilians are killed. In the end, though, the best days are when we can see real impact from the work we are doing.



## For more information

TOBAM is an asset management company offering innovative investment capabilities whose aim is to maximize diversification. TOBAM's Maximum Diversification® approach, supported by original, patented research and a mathematical definition of diversification, provides clients with diversified core exposure, in both the equity and fixed income markets. The company manages \$8 billion (as of September 2015) via its Anti-Benchmark® strategies in Equities and Fixed Income. Its team includes 38 investment professionals.

## Contacts:

### Paris Office

Christophe Roehri

+33 1 53 23 41 60

[Christophe.Roehri@tobam.fr](mailto:Christophe.Roehri@tobam.fr)

### New York Office

Stephane Detobel

+1 (646) 829-1621

[stephane.detobel@tobamusa.com](mailto:stephane.detobel@tobamusa.com)

Francis Verpoucke

+1 (646) 829-1622

[francis.verpoucke@tobamusa.com](mailto:francis.verpoucke@tobamusa.com)

### Client Service

Joe Kiwan

+33 1 53 23 41 66

[ClientService@tobam.fr](mailto:ClientService@tobam.fr)

## Disclaimer

This material is solely for the attention of institutional, professional, qualified or sophisticated investors and distributors. It is not to be distributed to the general public, private customers or retail investors in any jurisdiction whatsoever. This document is intended only for the person to whom it has been delivered.

Funds and/or SICAV specific information may have been provided for information solely to illustrate TOBAM's expertise in the strategy. Funds or the SICAV that might be mentioned in this document may not be eligible for sale in some states or countries and they may not be suitable for all types of investors. In particular, TOBAM funds are not registered for sale in the US, and this document is not an offer for sale of funds to US persons (as such term is used in Regulation S promulgated under the 1933 Act). This material is provided for information purposes only and does not constitute a recommendation, solicitation, offer, advice or invitation to purchase or sell any fund, SICAV or sub-fund or to enter in any transaction and should in no case be interpreted as such, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract for the same.

The information provided in this presentation relates to strategies managed by TOBAM, a French investment adviser registered with the U.S. Securities and Exchange Commission (SEC) under the U.S. Investment Advisers Act of 1940 and the Autorité des Marchés Financiers (AMF) and having its head office located at 49-53 Avenue des Champs Elysées, 75008 Paris. TOBAM's Form ADV is available free of charge upon request.

Investment involves risk. All investors should seek the advice of their legal and/or tax counsel or their financial advisor prior to any investment decision in order to determine its suitability. The value and income produced by a strategy may be adversely affected by exchange rates, interest rates, or other factors so that an investor may get back less than he or she invested.

Past performance and simulations based on thereon are not indicative of future results nor are they reliable indicators of future performance. Any performance objective is solely intended to express an objective or target for a return on your investment and represents a forward-looking statement. It does not represent and should not be construed as a guarantee, promise or assurance of a specific return on your investment. Actual returns may differ materially from the performance objective, and there are no guarantees that you will achieve such returns. Back tests do not represent the results of an actual portfolio, and TOBAM does not guarantee the accuracy of supporting data. The constraints and fees applicable to an actual portfolio would affect results achieved.

This material, including back tests, is based on sources that TOBAM considers to be reliable as of the date shown, but TOBAM does not warrant the completeness or accuracy of any data, information, opinions or results. TOBAM has continued and will continue its research efforts amending the investment process from time to time accordingly. TOBAM reserves the right of revision or change without notice, of the universe, data, models, strategy and opinions. TOBAM accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material. TOBAM can in no way be held responsible for any decision or investment made on the basis of information contained in this material. The allocations and weightings, as well as the views, strategies, universes, data, models and opinions of the investment team, are as of the date shown and are subject to change.

This document and the information herein is disclosed to you on a confidential basis and shall not be reproduced, modified, translated or distributed without the express written permission of TOBAM or TOBAM NORTH AMERICA and to the extent that it is passed on, care must be taken to ensure that any reproduction is in a form which accurately reflects the information presented here. This information could be presented by TOBAM NORTH AMERICA, a wholly-owned subsidiary of the TOBAM group of companies that is authorized to present the investment strategies of TOBAM, subject to TOBAM's supervision, but is not authorized to provide investment advice.

Copyrights: All text, graphics, interfaces, logos and artwork, including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement contained in this presentation, are owned by TOBAM and are protected by copyright and various other intellectual property rights and unfair competition laws. Trademarks: "TOBAM," "MaxDiv," "Maximum Diversification," "Diversification Ratio," "Most Diversified Portfolio," "Most Diversified Portfolios," "MDP" and "Anti-Benchmark" are registered trademarks. The absence of a product or service name from this list does not constitute a waiver of TOBAM trademark or other intellectual property rights concerning that name. Patents: The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are patented or patent pending. Knowledge, processes and strategies: The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are protected under unfair competition, passing-off and misappropriation laws. Terms of use: TOBAM owns all rights to, title to and interest in TOBAM products and services, marketing and promotional materials, trademarks and Patents, including without limitation all associated Intellectual Property Rights. Any use of the intellectual property, knowledge, processes and strategies of TOBAM for any purpose and under any form (known and/or unknown) in direct or indirect relation with financial products including but not limited to certificates, indices, notes, bonds, OTC options, warrants, mutual funds, ETFs and insurance policies (i) is strictly prohibited without TOBAM's prior written consent and (ii) requires a license.